ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.

Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in patients with asymptomatic severe AS.

Findings showed that higher biomarker levels were associated with worse outcomes in the EARLY-TAVR trial, however, regardless of baseline biomarkers, there was a benefit to early TAVR compared to clinical surveillance. The benefit of early TAVR was consistent across subgroups.

Interview Questions:

1. Could you remind us of the main aim and study design of EARLY-TAVR?

2. What were the main research questions for this substudy in regard to biomarkers?

3. What were the key findings?

4. What are your take-home messages?

5. What are the next steps?

Recorded on-site at ACC in Chicago, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Dan Brent, David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.